Literature DB >> 17014638

Linear IgA bullous disease of childhood: an experience from Kuwait.

Arti Nanda1, Richard Dvorak, Humoud Al-Sabah, Qasem A Alsaleh.   

Abstract

Linear IgA bullous disease of childhood is a rare autoimmune blistering disease. We report eight patients with this disease seen in our autoimmune bullous diseases clinic over a span of 12 years. They constituted 89% of the total number of those with linear IgA bullous disease of childhood seen during this period, with an age-adjusted minimum estimated incidence of 2.3 cases/million population/year. Males outnumbered females by a 1.7:1 ratio. The age at onset ranged between 10.5 months and 13 years, with a mean of 6.8 +/- 4.17 years. The majority of patients (62.5%) had moderately severe disease. Fifty percent of patients were observed to have an association with either an autoimmune disease (Crohn disease and post-streptococcal glomerulonephritis in one each) or an infection (beta-hemolytic streptococcal and hepatitis A virus infection in one each). The treatment of choice was dapsone alone or in combination with systemic steroids. Seventy-one percent of patients achieved complete remission by the end of 2 years. The study highlights the significance of systematic clinicoepidemiologic surveys from different regions.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17014638     DOI: 10.1111/j.1525-1470.2006.00279.x

Source DB:  PubMed          Journal:  Pediatr Dermatol        ISSN: 0736-8046            Impact factor:   1.588


  3 in total

1.  Linear IgA bullous dermatosis in tunisian children: 31 cases.

Authors:  Kharfi Monia; Khaled Aida; Karaa Amel; Zaraa Ines; Fazaa Becima; Kamoun Mohamed Ridha
Journal:  Indian J Dermatol       Date:  2011-03       Impact factor: 1.494

2.  The "Pearls" of Multidisciplinary Team: Conquering the Uncommon Rosette Rash.

Authors:  Nitin Verma; Charles Pickles; Muhammad Amjad Khan
Journal:  Case Rep Pediatr       Date:  2016-12-13

3.  Autoimmune Bullous Disease in Childhood.

Authors:  Andac Salman; Burak Tekin; Deniz Yucelten
Journal:  Indian J Dermatol       Date:  2017 Jul-Aug       Impact factor: 1.494

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.